% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

  • rosemariecorbin rosemariecorbin Apr 17, 2013 10:31 AM Flag

    in play with a frozen rope stock

    8:01AM Genomic Health announces publication of second positive validation of oncotype DX colon cancer test confirming its value beyond conventional markers (GHDX) 28.85 : Co announced that the Journal of Clinical Oncology (JCO) published positive results from the large CALGB 9581 clinical validation study of the Oncotype DX? colon cancer test in stage II colon cancer patients. The findings provide further confirmation that the Oncotype DX Recurrence Score (RS) results improve the ability to differentiate high recurrence risk disease from low, beyond conventional factors such as T-stage, mismatch repair (MMR) status, nodes examined, grade and lymphovascular invasion.

29.950.00(0.00%)Oct 25 4:00 PMEDT